Abstract: Proto-oncogene Raf1 serves as a part of the mitogen-activated protein kinases/extracellular signal-regulated kinase signal transduction pathway and regulates cell migration, apoptosis, and differentiation. Although a large number of studies have shown that Raf1 is overexpressed in various kinds of cancer, little is known about the association between Raf1 and miRNAs in thyroid carcinoma. This study proves that Raf1 is overexpressed in thyroid cancer, which has been confirmed by many other studies. Besides, we identify that Raf1 is a direct target of miR-15a/b, miR-16, and miR-195 by dual luciferase reporter assay. We also find that the expression of miR-195 is downregulated in 50 pairs of thyroid tumor tissues compared to the adjacent nontumor tissues, while there is no difference in the expression of miR-15a/b and miR-16 between the groups. Furthermore, exogenous overexpression of miR-195 significantly inhibits the protein expression of Raf1 and blocks the thyroid cancer cell proliferation. Our findings delineate a novel mechanism for the regulation of Raf1 in thyroid cancer, which may help to provide a new direction for the treatment of thyroid cancer.
Introduction
The incidence of thyroid cancer is increasing rapidly in recent years, 1 making it the most common endocrine relevant tumor. 2 There are four major types of thyroid cancer: papillary, follicular, medullary, and anaplastic. Thyroid cancer is three times more common in women than in men. Although the risk factors that have been identified for thyroid cancer include a family history of goiter, exposure to high levels of radiation, and certain hereditary syndromes, the cause of thyroid cancer is still unclear.
miRNA is a small noncoding RNA molecule that plays a key role in posttranscriptional regulation of gene and RNA silencing. 3, 4 Disorder of miRNAs is involved in the development of diverse tumors. 5, 6 The circulating miRNAs have been identified as specific biomarkers for the diagnosis of various cancers, such as lung cancer, 7, 8 kidney diseases, 9 breast cancer, 10 hematologic cancer, 11 prostate cancer, 12 and thyroid cancer. 13 Results from miRNA microassays reveal that miRNAs including miR-146, miR-221, miR-222, and miR181 are upregulated in thyroid cancer, whereas miRNAs including miR-15, miR-551, miR873, miR-876, and miR-203 are significantly deregulated in thyroid cancer. 14, 15 miR-15a/b, miR-16, and miR-195 are the members of the miR-15 family. A study by Calin et al found that miR-15 and miR-16 are downregulated or deleted in 68% of chronic lymphocytic leukemia. 16 Besides, miR-15a/16-1 deletion can accelerate the proliferation of B-cells by regulating the expression of genes associated with cell cycle. 17 miR-15a/16-1 can also repress the expression of oncogene BCL-2. 18 Recent studies submit your manuscript | www.dovepress.com
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Wang et al reveal that exogenous miR-195 transfection can inhibit the proliferation of colorectal cancer cells 19 and hepatocellular carcinoma cells. 20 Rescuing the expression of miR-195 in breast cancer cells significantly inhibits cell survival and promotes cellular apoptosis. 21 As a proto-oncogene, Raf1 is an effector of RAS that is activated by many growth factors 22 and guides the receptor signals from cell membrane to nucleus. 23 Once activated, Raf1 phosphorylates and activates Raf-MEK-ERK pathway, which then regulates cell cycle, proliferation, apoptosis, and migration. [24] [25] [26] Although massive studies have shown that Raf1 is overexpressed in various kinds of cancers, the mechanism for the regulation of Raf1 by miRNA is indistinct.
In this study, we show for the first time that Raf1 is upregulated in thyroid cancer and identified that Raf1 is a target gene of miR-15a/b, miR-16, and miR-195. We also demonstrate miR-195 is downregulated in thyroid cancer, while there is no difference in the expression of miR-15a/b and miR-16. Overexpression of miR-195 markedly suppresses the growth of thyroid cancer cells. This study reveals a novel negative regulatory mechanism of Raf1, which can provide us a new direction for thyroid cancer therapy.
Materials and methods clinical samples
A total of 50 matched neoplastic and normal human thyroid tissues are obtained from surgical specimens and immediately frozen in -80°C. Thyroid tumors are collected from patients undergoing surgical resections from 2011 to 2014 in the Zhejiang Cancer Hospital. All patients have a clear histologic diagnosis of thyroid cancer based on the American Joint Committee on Cancer. Every sample enrolled in this study is obtained with the patients' informed consent, and the study protocol is approved by the Medical Ethics and Human Clinical Trial Committee.
cell culture and transfection
Human thyroid cancer cell lines B-CPAP and ACT-1 are cultured in 1640 medium supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 U/mL streptomycin at 37°C in 5% CO 2 27 The expression of Raf1 is assessed using the following primers: Raf1-forward, 5′-GGGAGCTTGGAAGACGATCAG-3′; Raf1-reverse, 5′-ACACGGATAGTGTTGCTTGTC-3′; glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-forward, 5′-CTGGGCTACACTGAGCACC-3′; GAPDHreverse, 5′-AAGTGGTCGTTGAGGGCAATG-3′. All the quantitations of PCR data are performed according to the method described earlier. 28 
Western blot analysis
Cells are lysed in radio-immunoprecipitation assay lysis buffer supplemented with protease inhibitor mixture, and the protein concentration is quantified using an Enhanced BCA Protein Assay kit (Beyotime). A 30 µg of total protein extract is separated by 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane (EMD Millipore, Billerica, MA, USA). After blocking with 5% nonfat dry milk, the samples are incubated with mouse anti-GAPDH monoclonal antibody (KangChen Biotech, Shanghai, People's Republic of China) and rabbit antiRaf1 monoclonal antibody (Abcam, Cambridgeshire, UK).
cell count assay
In a 6-well plate, 1×10 5 LV-NC or LV-miR-195 Lentivirusinfected cells are seeded. Cells are harvested and counted every day after seeding. Each point of the growth curve is the average of triplicates.
Dual luciferase reporter assay
The Raf1 3′-untranslated region (3′-UTR) is amplified and cloned into the pmiR-REPORT™ vector (Thermo Fisher Scientific, Waltham, MA, USA). B-CPAP and ACT-1 cells are seeded in 24-well plate and cotransfected with 100 ng wild-type (WT) or deletion reporter vector and 10 ng pmiR-REPORT™-β gal control plasmid in the presence of 100 nM either miR-15a/b, miR-16, miR-195 mimics, or negative control mimics. After 36 hours, the luciferase activity is measured using the Dual Luciferase Reporter Assay System (Promega Corporation, Fitchburg, WI, USA). All experiments are performed independently in triplicate. Immunohistochemistry (IHC) staining is performed using UltraSensitive™ S-P kit (MAIXIN-BIO, Fuzhou, People's Republic of China). Formalin-fixed, paraffin-embedded thyroid cancer tissue slides are heated (high pressure, 100 seconds) for antigen retrieval with citrate buffer (pH =6.0) as the solution. Endogenous peroxidase activity is blocked by 3% hydrogen peroxide. Slides are incubated with rabbit anti-Raf1 monoclonal (Abcam, 1:100) after blocking with goat serum. Finally, the slides are immunostained with UltraSensitive™ S-P kit (Rabbit, MAIXIN-BIO) and DAB Detection kit (MAIXIN-BIO).
Bioinformatics analysis
TargetScan software (Whitehead Institute for Biomedical Research, Boston, USA) is used to analysis the 3′UTR of Raf1.
statistical analysis
All data are analyzed by Statistical SPSS Version 17.0 (IBM, Chicago, USA). Differences between two groups are estimated with paired t-test (two tail), and the data are expressed as mean ± standard deviation. For all the tests, differences with P,0.05 are considered statistically significant.
Results
raf1 protein level is elevated in thyroid cancer
The protein level of Raf1 is determined by immunohistochemical staining using a Raf1 monoclonal antibody. As shown in Figure 1 , Raf1 is overexpressed in thyroid cancer tissue (right) compared to matched normal thyroid tissues (left). Both tumor and normal thyroid tissues are dissected from the same patient. The results show that thyroid cancer has a higher level expression of Raf1 compared to the adjacent tissues.
The
29 So, we analyze the 3′UTR of Raf1 by bioinformatics analysis to identify potential binding miRNAs. Figure 2 shows that miR-15 clusters, miR-19, miR-125 clusters, and miR-7 may be the potential miRNAs that can interact with Raf1 3′UTR. 
Among these potential miRNAs, we focus our attention on miR-15 family, which is known as tumor suppressor. To further confirm this hypothesis, luciferase reporter vectors containing the predicted seed sequences in the 3′UTR of Raf1 (WT-UTR) and the deletion Raf1 3′UTR clone (deletion-UTR) that has a 12-nucleotide deletion in the common binding sites of miR-15a/b, miR-16, and miR-195 are constructed ( Figure 3A) . From the results, we can find that miR-15a/b, miR-16, and miR-195 mimics can repress the luciferase activity of Raf1-WT-UTR compared to control mimics. While there is no significant difference when cotransfected with the Raf1 deletion UTR ( Figure 3B-D) , indicating miR-15a/b, miR-16, and miR-195 can directly bind to the 3′-UTR of Raf1 mRNA.
mir-195 is downregulated in thyroid cancer tissues
The expression of miR-15a/b, miR-16, and miR-195 in 50 paired thyroid tumor tissue samples is measured by real-time PCR. As shown in Figure 4C , miR-195 is significantly Figure 5C ).
mir-195 suppresses the proliferation of thyroid cancer cells
Previous studies have suggested that Raf1 is involved in cellular proliferation, so we decide to determine whether overexpression of miR-195 could suppress the growth of thyroid cancer. The growth curve assays were conducted by counting the cell number. As expected, cellular proliferation is significantly impaired in miR-195 overexpressing thyroid cancer cells (Figure 6 ). These results indicate that miR-195 plays an important role in regulating the proliferation of thyroid cancer cells.
Discussion
During the decades, there has been a notable trend in the increase of thyroid cancer, although the specific reasons for this trend are still undefined. 30 Many genetic factors involved in thyroid cancer have been discovered. Activating mutations of genes such as BRAF, RET, and RAS are associated with the initiation, progression, and outcome of thyroid cancer by driving activation of mitogen-activated protein kinases and mammalian target of rapamycin pathways.
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The Raf kinase family is a three serine/threonine-specific protein kinase and composed of A-Raf, B-Raf, and Raf1. 
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Wang et al In the direct downstream of RAS, Raf1 can be activated by RAS and promotes the activation of the downstream signaling cascade RAF/MEK/ERK, which is important in the regulation of cell proliferation, apoptosis, and differentiation. 33 In the present study, we find that thyroid cancer tissues have higher Raf1 expression compared to the adjacent tissues (Figure 1) .
By inhibiting or degrading the target mRNA, miRNAs play a key role in the posttranscriptional regulation of the target gene. 34 A large number of studies have proved that dysregulation of miRNAs has close correlations with the progress of thyroid cancer. Overexpression of miRNAs, such as miR-146 and miR-34a, in thyroid cancer promote cell proliferation. 35, 36 While miR-204, miR-181, and miR-101, which are deregulated in thyroid cancer, can suppress cancer proliferation and metastasis. 37 A somatic Raf1 mutation occurs in ~40%-60% of papillary thyroid cancer, which makes the design of targeted drug more difficult. However, the characters that both the WT and the mutation type of Raf1 share a same 3′UTR pushes drugs based on miRNA more striking. Bioinformatic analysis of Raf1 3′UTR reveals that miR-15 clusters may be the key potential miRNAs, which stand in the key regulation cross Raf1 (Figure 2 ). Further luciferase report assay confirms that Raf1 is a target gene of miR-15a/b, miR-16, and miR-195 (Figure 3) .
Prostate tumor xenografts demonstrate that overexpression of miR-15a and miR-16 can induce growth arrest and promotes apoptosis. 38 In this study, the level of miR-15a/b and miR-16 in 50 pairs of thyroid cacner tissues is detected. However, the expression of miR-15a/b and miR-16 in cancer tissues displays a similar expression as noncancer tissues ( Figure 4A and B) . miR-195, another member of miR-15 clusters, is decreased in colon cancer, 39 gastric cancer, 40 breast cancer, 41 hepatocellular carcinoma, 42 bladder cancer, 43 and non-small-cell lung cancer. [44] [45] [46] Regaining the level of miR-195 in lung cancer cell inhibits cell proliferation and metastasis by targeting HDGF and IGF1R. 47, 48 Recent studies reveal that miR-195 is involved in triple-negative breast cancer and the drug sensitivity of breast cancer. 49, 50 Herein, we find that miR-195 is downregulated in thyroid cancer ( Figure 4C ). We also confirm that miR-195 can repress the protein expression rather than the mRNA expression of Raf1 by interacting with the 3′UTR of Raf1 mRNA ( Figures 3D  and 5 ). These findings indicate that the regulation of Raf1 by miR-195 is mostly through protein translation inhibition rather than the degradation of mRNA.
Conclusion
In this study, we identify that Raf1 is overexpressed in thyroid cancer, which may be mainly caused by the deregulation of miR-195. Meanwhile, we confirm that miR-195 can inhibit the proliferation of thyroid cancer cells. Taken together, our data reveal a novel mechanism for the regulation of Raf1 in thyroid cancer, which may facilitate the advancement of clinical diagnosis, treatment, and prevention in thyroid cancer.
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